<DOC>
	<DOC>NCT00878930</DOC>
	<brief_summary>The objectives of this study is to obtain information of Faslodex use in the treatment of breast cancer in the clinical practice in Argentina.</brief_summary>
	<brief_title>Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer</brief_title>
	<detailed_description>In Argentina, Faslodex is indicated for treating postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer with recurrence during or after adjuvant anti-oestrogen therapy or disease progression during anti-oestrogen treatment. This study will provide information regarding the acceptability and compliance of Argentina patients to Faslodex and will provide information regarding the efficacy of this treatment in local population.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Postmenopausal women with hormone receptorpositive locally advanced or metastatic breast cancer with recurrence during or after adjuvant antiestrogen therapy or disease progression during antiestrogen treatment, currently receiving Faslodex Signature of the informed consent Any contraindication to Faslodex administration</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Faslodex</keyword>
	<keyword>Acceptability</keyword>
	<keyword>Compliance</keyword>
	<keyword>Efficacy</keyword>
</DOC>